

New-to-Market Medical Pharmacy Products Currently Under Clinical Review by Medica

Updated 1/30/2024

Brand name	Generic name	J code	National Drug Codes (NDCs)	Date of FDA approval
Adzynma	adamts13, recombinant-krhn	J3590	Multiple	November 8, 2023
Alyglo	Immune globulin-stwk	J1599	Multiple	December 15, 2023
Aphexda	motixafortide	J3490	82737-0073-01	September 24, 2023
Casgevvy	exagamglogene autotemcel	J3590	51167-0290-09	December 8, 2023
Cosentyx IV	secukinumab	J3590	00078-1168-61	October 6, 2023
Daxxify	daxibotulinumtoxina-lanm	J3590	72960-0111-01, 72960-0112-01	August 11, 2023
Loqtorzi	toripalimab-tpzi	J9999	70114-0340-01	October 27, 2023
Lyfgenia	lovotibeglogene autotemcel	J3590	73554-1111-01	December 8, 2023
Omvox	mirikizumab-mrkz	J3590	00002-7575-01 , 00002-8011-27	October 26, 2023
Pombiliti	cipaglucosidase alfa-atga	J3590	71904-0200-01, 71904-0200-02, 71904-0200-03	September 28, 2023
Ryzneuta	efbemalenograstim alfa-vuxw	J3590	73491-0627-01	November 16, 2023

Note: Drugs recently removed from this list have been addressed under new [Medica drug management policies](#).

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing are outside of Medica's control. Medica reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in [the New-to-Market Medical Pharmacy Products coverage policy](#).